Skip to main content

Table 1 Baseline patient characteristics

From: Long-term prognostic significance of rising PSA levels following radiotherapy for localized prostate cancer – focus on overall survival

  All (n = 295) LDR-BT (n = 94) HDR-BT + EBRT (n = 66) EBRT (n = 135)
Patient age median (range) 71(49–83) 69(49–81) 72(63–81) 71(52–83)
Follow-up period/months median (range) 108(7–157) 120(8–150) 111(7–157) 105(9–149)
T stage > 2a 21% 5% 36% 25%
Gleason score >6 13% 3% 18% 17%
Primary PSA/ng/ml median (range) 9(1–300) 7(1–15) 13(1–300) 10(1–150)
Low risk patientsa 43% 65% 27% 35%
Intermediate risk patientsb 29% 35% 24% 26%
High risk patientsc 29% 0% 49% 39%
NHT 44% 35% 56% 47%
NHT/months median (range) 4(1–28) 3(1–8) 5(1–28) 5(1–18)
  1. aNo risk factors: PSA < 10 ng/ml, Gleason score < 7, cT-stage <2b
  2. bOne risk factors: PSA 10–20 ng/ml or Gleason score = 7 or cT-stage = 2b/c
  3. cTwo risk factors or PSA > 20 ng/ml or Gleason score >7 or cT-stage >2b/c